Clinical Trial Update: Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating hTERT mRNA-transfected dendritic cell vaccines for metastatic prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• hTERT mRNA-transfected dendritic cell vaccine

Snippet

Sponsor: University of Florida | Conditions: Metastatic Prostate Cancer | Phase 1, Phase 2 | Status: WITHDRAWN